DM Kendall, MC Riddle, J Rosenstock, D Zhuang, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg), −0.6 ±
0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs. placebo), yielding placebo-adjusted
reductions of −1.0% (10 μg) and −0.8% (5 μg). In the evaluable population, exenatide- ... Cited by 548 - Related articles - All 11 versions
DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and
suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food
intake. Therapeutic approaches for enhancing incretin action include ... Cited by 416 - Related articles - All 10 versions
- ►endojournals.org F Fehse, M Trautmann, JJ Holst, AE Halseth, N … - Journal of Clinical …, 2005 - Endocrine Soc Context: First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose) is
reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has glucoregulatory
activities in DM2, including glucose-dependent enhancement of insulin secretion. Cited by 123 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, … - Annals of internal …, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or sulfonylureas for
treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are commonly used, but the efficacy
of exenatide with a TZD has not been reported. ... Objective: To compare the effects of ... Cited by 121 - Related articles - BL Direct - All 5 versions
V Fonseca, A Schweizer, D Albrecht, MA Baron, I … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Type 2 diabetes is difficult to manage in patients with a long history
of disease requiring insulin therapy. Moreover, addition of most currently available oral antidiabetic
agents increases the risk of hypoglycaemia. Vildagliptin is a dipeptidyl peptidase-IV ... Cited by 105 - Related articles - BL Direct - All 4 versions
- ►endojournals.org BR Gedulin, SE Nikoulina, PA Smith, G Gedulin, LL … - Endocrinology, 2005 - Endocrine Soc The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin
sensitivity, and ß-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker
rats. After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle ... Cited by 100 - Related articles - All 5 versions
JB Buse, DC Klonoff, LL Nielsen, X Guan, CL Bowlus, … - Clinical therapeutics, 2007 - Elsevier For this interim analysis, data were pooled from patients who completed 1 of three 30-week,
multicenter, double-blind, placebo-controlled trials and their open-label extensions. In the initial
trials, subjects were randomized to BID 5-pg exenatide, 10-pg exenatide, or placebo for ... Cited by 92 - Related articles - All 3 versions
BE Dunning, JE Foley, B Ahren - Diabetologia, 2005 - Springer Abstract Although there is abundant evidence that hyper- glucagonaemia plays a key role in
the development of hy- perglycaemia in type 2 diabetes, efforts to understand and correct this
abnormality have been overshadowed by the emphasis on insulin secretion and action. ... Cited by 70 - Related articles - BL Direct - All 3 versions
JF Gautier, S Fetita, E Sobngwi, C Salaün-Martin - Diabetes and Metabolism, 2005 - Elsevier Incretin hormones are defined as intestinal hormones released in response to nutrient
ingestion, which potentiate the glucose-induced insulin response. In humans, the incretin effect
is mainly caused by two peptide hormones, glucose-dependent insulin releasing ... Cited by 65 - Related articles - All 3 versions
